Why Kevin Lee Left Pfizer To Push Bicycles
This article was originally published in Scrip
Executive Summary
The pharma wires have been busy recently with news of droves of big pharma executives leaving their posts to take up the top spot at small biotech companies. The latest is Dr Kevin Lee, the former chief scientific officer of the Rare Disease Research Unit at Pfizer. Here he tells Scrip's Sukaina Virji what prompted him to leave the glamorous life of a big pharma executive and take up his new job as chief executive officer of tiny Cambridge, UK-based biotech Bicycle Therapeutics.
You may also be interested in...
Finance Watch: Bicycle Spins Toward Clinic With $52m Round; Stock Spikes Spur Offerings
Bicycle closes a $52m Series B to test its bicyclic peptides in humans, while Decipera, Harpoon and TP Therapeutics also top a $263m list of recent venture capital deals. In public company financings, Alnylam, Aerie and others price offerings to raise cash while their stocks are on the rise.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.